Clinical Trial Update: An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 exploratory study evaluating safety and immunogenicity of HPV16+ immunotherapy VB10.16 in women with high-grade cervical intraepithelial neoplasia (CI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Cin 2 3
• High-grade Squamous Intraepithelial Lesion

Drugs mentioned

• VB10.16

Snippet

Sponsor: Nykode Therapeutics ASA | Conditions: High Grade Cervical Intraepithelial Neoplasia | Phase 1, Phase 2 | Status: COMPLETED